The latest published report by Polaris Market Research The report “Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology (Immunoassay, NGS, PCR, In Situ Hybridization, Microarray, Mass Spectrometry, Others); By Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma, Others); By Biomarker Type (Genomic Biomarkers, Protein Biomarkers, Others); By Application (Personalized Medicine, Diagnostics, Prognostics, Biomarker Discovery, Research); By Regions – Segment – Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Global cancer/tumor profiling market was valued at USD 8.67 billion in 2019 and is expected to reach USD 15.32 billion by 2027 to exhibit a CAGR of 7.15% over the forecast period (2020-2027) Increasing demand for tumor profiling and diagnosis and therapy techniques is driven by oncologists. Increased use of biomarkers in tumor profiling and increasing use of next-generation cancer profiling sequencing methods are some of the main factors driving the growth of the tumor profiling market. Tumor profiling is used to evaluate the metabolism, properties, and mutations of the tumor that can assist discover effective therapies. Drugs that target these mutated kinases can be discovered and developed based on genetic modification. The profiling is considered a requirement to increase the sensitivity of kinases-focused medications because they rely on individual tumors genetic composition. Thus, these mutated profiles of DNA tumors help to create specific anticarcinogenic treatments
Market participants such as : Abott Molecular, Agendia, Boreal Genomics Inc, BD Biosciences, Caris Life Sciences, F. Hoffmann-La Roche Ltd, Foundation Medicine, Genscript Biotech Corporation, Guardant Health, Inc., Helomics Corporation, Histogene X, Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., Nanostring Technologies, Inc., Neogenomics, Inc., Omniseq, Perthera, Qiagen N.V., Ribomed Biotechnologies, Inc., Roche Molecular Systems Inc., Sysmex Corporation and Tempus Labs.
Certified techniques have been identified that can reduce the time taken to identify tumors and stages of advancement along with improved support for cancer research. Moreover, major investments by major biotechnology companies for the development of new therapies and new techniques of drug design are being witnessed across countries. This has significantly driven market growth and is expected to sustain growth during the forecast period. Biomarkers play a significant part in the design of a drug regime for cancer patients by quickly developing gene profiling techniques and individualizing targeted therapies. Currently, genome-based prognostic biomarkers can be used to prognosticate multiple kinds of cancer in the clinical phases. Researchers, however, contend that conversion difficulties are hindering the broad divide between the phase of biomarker discovery and their clinical conversion. The acquisition of tumor genomic data is seen as the most significant step in cancer prediction, diagnosis, and therapy.
Next-Generation Sequencing (NGS) is a sophisticated technique for the sequence that can be used for accurate tumor DNA genomic sequencing. The interpreted data contribute much more quickly to the assessment of tumor purity and the magnitude of disease progression. The primary benefit of NGS is the complete exotic sequence which helps examine all protein-coding areas of the human genome. It also enables whole genome sequencing to be useful for analysis of protein coding and non-coding areas in the human genome. Such advances in technology are one of the primary drivers of global cancer/tumor profiling market.
Moreover, the growing demand for personalized medicine further provides substantial opportunities for the tumor profiling market. The personalized medicine is defined as typical care in the treatment that is customized as per an individual patient. There have been several types of research going on presently to develop personal medicine based on the patients. Several factors should be considered before providing personal medicine to a patient. Firstly, the doctors have to detect the type or the symptoms of cancer that can be developed in a patient. Detection is important for the surgeon or the doctor, to find the best suited therapy that can treat the person. For developing a personalized medicine tumor profiling need to be taken into account as these tests will eventually reveal the various conditions of the patients such as detection of the individual developing a specific type of disease.
To get Incredible Discounts on this Premium Report, Click At: https://www.polarismarketresearch.com/industry-analysis/cancer-tumor-profiling-market/request-for-discount-pricing
Table of Contents
Overview and Scope
Cancer/tumor Profiling Market Insights
Cancer/tumor Profiling Market Size and Forecast by Transducer Frequency Range
- In Situ Hybridization
- Mass Spectrometry
Cancer/tumor Profiling Market Size and Forecast by Cancer Type
Cancer/tumor Profiling Market Size and Forecast by Biomarker Type
- Genomic Biomarkers
- Protein Biomarkers
Cancer/tumor Profiling Market Size and Forecast by Application
- Personalized Medicine
- Biomarker Discovery
Cancer/tumor Profiling Market Size and Forecast by Region
List of Tables
Table 1 Global cancer/tumor profiling market (USD Million) 2016 – 2027
Table 2 Global cancer/tumor profiling market by region 2016 – 2027 (USD Million)
Table 3 Global cancer/tumor profiling market by technology, 2016 – 2027 (USD Million)
List of Figures
FIG 1. Market snapshot
FIG 2. Market segmentation & scope
FIG 3. Global Cancer/tumor Profiling market size and growth prospects, 2016 – 2027
Have Questions? Or make an Inquiry before buying this report Speak to Our Industry Expert: https://www.polarismarketresearch.com/industry-analysis/cancer-tumor-profiling-market/speak-to-analyst
The report can be customized on the basis of regional analysis, segment analysis, industry outlook and competitive analysis. Some of the major focus points which are covered in the report include:
- Industry Trends, opportunity and challenges in the market
- Role of key players across the value chain
- End-User analysis to define the market strategy
- Competitive mapping
- Regional and country level breakdown
These insights are included in the report which would help you to have a realistic overview of the overall market including the competition, investment opportunities, restraints and challenges, regulatory factors which might affect the market growth. Moreover, the report would help to identify the regional market growth opportunities for different segments covered in the report.
Direct Purchase Licensed Copy Of Cancer Tumor/Profiling Market: https://www.polarismarketresearch.com/checkouts/6801
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavour to deliver value-added business solutions to our customers.
Polaris Market Research